CELEX: 22017D2034
Language: en
Date: 2016-04-29 00:00:00
Title: Decision of the EEA Joint Committee No 84/2016 of 29 April 2016 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2017/2034]

16.11.2017   
               
               
                  EN
               
               
                  Official Journal of the European Union
               
               
                  L 300/28
               
            DECISION OF THE EEA JOINT COMMITTEE
      No 84/2016
      of 29 April 2016
      amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2017/2034]
      THE EEA JOINT COMMITTEE,
      Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,
      Whereas:
      
                  (1)
               
               
                  Commission Implementing Regulation (EU) 2016/105 of 27 January 2016 approving biphenyl-2-ol as an existing active substance for use in biocidal products for product-types 1, 2, 4, 6 and 13 (1) is to be incorporated into the EEA Agreement.
               
            
                  (2)
               
               
                  Commission Implementing Regulation (EU) 2016/124 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-type 4 (2) is to be incorporated into the EEA Agreement.
               
            
                  (3)
               
               
                  Commission Implementing Regulation (EU) 2016/125 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-types 2, 3, 11 (3) is to be incorporated into the EEA Agreement.
               
            
                  (4)
               
               
                  Commission Implementing Regulation (EU) 2016/131 of 1 February 2016 approving C(M)IT/MIT (3:1) as an existing active substance for use in biocidal products for product-types 2, 4, 6, 11, 12 and 13 (4) is to be incorporated into the EEA Agreement.
               
            
                  (5)
               
               
                  Commission Implementing Decision (EU) 2016/107 of 27 January 2016 not approving cybutryne as an existing active substance for use in biocidal products for product-type 21 (5) is to be incorporated into the EEA Agreement.
               
            
                  (6)
               
               
                  Commission Implementing Decision (EU) 2016/108 of 27 January 2016 not approving 2-Butanone, peroxide as an existing active substance for use in biocidal products for product-types 1 and 2 (6) is to be incorporated into the EEA Agreement.
               
            
                  (7)
               
               
                  Commission Implementing Decision (EU) 2016/109 of 27 January 2016 not to approve PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-types 1, 6 and 9 (7) is to be incorporated into the EEA Agreement.
               
            
                  (8)
               
               
                  Commission Implementing Decision (EU) 2016/110 of 27 January 2016 not approving triclosan as an existing active substance for use in biocidal products for product-type 1 (8) is to be incorporated into the EEA Agreement.
               
            
                  (9)
               
               
                  Commission Implementing Decision (EU) 2016/135 of 29 January 2016 postponing the expiry date of approval of flocoumafen, brodifacoum and warfarin for use in biocidal products for product-type 14 (9) is to be incorporated into the EEA Agreement.
               
            
                  (10)
               
               
                  Annex II to the EEA Agreement should therefore be amended accordingly,
               
            HAS ADOPTED THIS DECISION:
      Article 1
      The following points are inserted after point 12zzzb (Commission Implementing Regulation (EU) 2015/985) of Chapter XV of Annex II to the EEA Agreement:
      
                  ‘12zzzc.
               
               
                  
                     32016 R 0105: Commission Implementing Regulation (EU) 2016/105 of 27 January 2016 approving biphenyl-2-ol as an existing active substance for use in biocidal products for product-types 1, 2, 4, 6 and 13 (OJ L 21, 28.1.2016, p. 74).
               
            
                  12zzzd.
               
               
                  
                     32016 D 0107: Commission Implementing Decision (EU) 2016/107 of 27 January 2016 not approving cybutryne as an existing active substance for use in biocidal products for product-type 21 (OJ L 21, 28.1.2016, p. 81).
               
            
                  12zzze.
               
               
                  
                     32016 D 0108: Commission Implementing Decision (EU) 2016/108 of 27 January 2016 not approving 2-Butanone, peroxide as an existing active substance for use in biocidal products for product-types 1 and 2 (OJ L 21, 28.1.2016, p. 83).
               
            
                  12zzzf.
               
               
                  
                     32016 D 0109: Commission Implementing Decision (EU) 2016/109 of 27 January 2016 not to approve PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-types 1, 6 and 9 (OJ L 21, 28.1.2016, p. 84).
               
            
                  12zzzg.
               
               
                  
                     32016 D 0110: Commission Implementing Decision (EU) 2016/110 of 27 January 2016 not approving triclosan as an existing active substance for use in biocidal products for product-type 1 (OJ L 21, 28.1.2016, p. 86).
               
            
                  12zzzh.
               
               
                  
                     32016 R 0124: Commission Implementing Regulation (EU) 2016/124 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-type 4 (OJ L 24, 30.1.2016, p. 1).
               
            
                  12zzzi.
               
               
                  
                     32016 R 0125: Commission Implementing Regulation (EU) 2016/125 of 29 January 2016 approving PHMB (1600; 1.8) as an existing active substance for use in biocidal products for product-types 2, 3, 11 (OJ L 24, 30.1.2016, p. 6).
               
            
                  12zzzj.
               
               
                  
                     32016 R 0131: Commission Implementing Regulation (EU) 2016/131 of 1 February 2016 approving C(M)IT/MIT (3:1) as an existing active substance for use in biocidal products for product-types 2, 4, 6, 11, 12 and 13 (OJ L 25, 2.2.2016, p. 48).
               
            
                  12zzzk.
               
               
                  
                     32016 D 0135: Commission Implementing Decision (EU) 2016/135 of 29 January 2016 postponing the expiry date of approval of flocoumafen, brodifacoum and warfarin for use in biocidal products for product-type 14 (OJ L 25, 2.2.2016, p. 65).’
               
            Article 2
      The texts of Implementing Regulations (EU) 2016/105, (EU) 2016/124, (EU) 2016/125 and (EU) 2016/131 and Implementing Decisions (EU) 2016/107, (EU) 2016/108, (EU) 2016/109, (EU) 2016/110 and (EU) 2016/135 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
      Article 3
      This Decision shall enter into force on 30 April 2016, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).
      Article 4
      This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.
      
         Done at Brussels, 29 April 2016.
         
            
               For the EEA Joint Committee
            
            
               The President
            
            Claude MAERTEN
         
      
      
         (1)  OJ L 21, 28.1.2016, p. 74.
      
         (2)  OJ L 24, 30.1.2016, p. 1.
      
         (3)  OJ L 24, 30.1.2016, p. 6.
      
         (4)  OJ L 25, 2.2.2016, p. 48.
      
         (5)  OJ L 21, 28.1.2016, p. 81.
      
         (6)  OJ L 21, 28.1.2016, p. 83.
      
         (7)  OJ L 21, 28.1.2016, p. 84.
      
         (8)  OJ L 21, 28.1.2016, p. 86.
      
         (9)  OJ L 25, 2.2.2016, p. 65.
      
         (*1)  No constitutional requirements indicated.